好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Investigating the Role of GBA1 Mutations in Propagation of Lewy Pathology
Movement Disorders
P3 - Poster Session 3 (11:45 AM-12:45 PM)
5-001

To investigate mechanisms underlying the clinical observation that GBA1 mutations are associated with faster progression of motor and cognitive symptoms in Parkinson’s Disease (PD).

Mutations in the gene glucosidase, beta acid 1 (GBA1) are the strongest genetic risk factor for PD and are associated with accelerated disease progression. Our Drosophila GBA1 deficient model revealed alterations in exosomes which may act as vehicles to accelerate protein aggregate spread. We are elucidating how GBA1 deficiency influences endolysosomal trafficking and exosome biogenesis.

We are using a Drosophila model of GBA1 deficiency (GBAdel) and human induced pluripotent stem cells (iPSCs) model from an PD patient heterozygous for GBAIVS2+1 (GBAIVS PD). GBAIVS PD iPSC-neurons are compared to isogenic GBAWT PD generated by CRISPR/Cas9 and age- and sex-matched healthy control iPSCs using StemCell Technologies reagents and protocols. EVs were isolated from Drosophila GBAdel hemolymph or conditioned media of iPSC-neurons by size exclusion chromatography.

Expression of alpha-synuclein in flight muscle in Drosophila resulted in increased spread of oligomerized alpha-synuclein in the brain. GBAIVS PD dopaminergic neurons have increased ubiquitinated proteins and larger early endosome and lysosome compartments compared to controls.  Preliminary results detected synuclein aggregates in EVs isolated from neuronal conditioned media.

Our Drosophila and human iPSC-neuron models support the hypothesis that GBA1 deficiency alters exosomes, which may mediate accelerated spread of Lewy pathology. We are now examining whether exosomes from GBA deficient neurons can propagate Lewy pathology more rapidly than exosomes isolated from control neurons. Understanding how GBA1 influences Lewy pathology spread could lead to new therapeutic targets to slow PD progression.

Authors/Disclosures
Anna Park (VA Puget Sound Health Care System)
PRESENTER
Miss Park has nothing to disclose.
Sarah Fish (SIBCR) Sarah Fish has nothing to disclose.
Ella Chiu Miss Chiu has nothing to disclose.
Malia Callier Miss Callier has nothing to disclose.
Joshua Weiss, PharmD Mr. Weiss has nothing to disclose.
Arnav Khera Mr. Khera has nothing to disclose.
Jeremy R. Weiss Mr. Weiss has nothing to disclose.
Selina Yu Selina Yu has nothing to disclose.
Marie Y. Davis, MD, PhD (VA Puget Sound) Dr. Davis has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. The institution of Dr. Davis has received research support from NIH NINDS. The institution of Dr. Davis has received research support from University of Washington Institute for Stem Cell and Regenerative Medicine. The institution of Dr. Davis has received research support from VA BLRD. Dr. Davis has received personal compensation in the range of $500-$4,999 for serving as a study section grant reviewer with NIH. Dr. Davis has received personal compensation in the range of $500-$4,999 for serving as a Grant reviewer with Parkinson's Foundation.